Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

Key Inclusion Criteria:

• General:

1. Must be willing and able to provide written, signed informed consent.

2. Age: Subjects ≥ 50 and ≤ 89 years of age at the time of signing the informedconsentStudy eye:

3. Diagnosis of wAMD, including symptomatic macular PCV, confirmed by the CentralReading Center

4. The macular neovascularization lesion must be confirmed as determined by theCentral Reading Center based on SD-OCT imaging at screening.

5. BCVA ≤ 20/32 and ≥ 20/250 (≤ 78L and ≥ 30L ETDRS letters)

6. History of ≥ 2 anti-VEGF injections prior to trial entry with meaningfulresponse to anti-VEGF and continued need for anti-VEGF treatment

7. Response to anti-VEGF at trial entry

8. Must be pseudophakic

Key Exclusion Criteria:

• Study or Fellow Eye:

1. Prior gene therapy, either eye

2. Any active ocular/intraocular infection or inflammation (e.g., blepharitis,infectious conjunctivitis, keratitis, scleritis, uveitis) or history ofidiopathic or autoimmune-associated uveitis, either eye

3. History of retinal disease other than wAMD or PCV, study eye

4. Any condition preventing visual acuity improvement (e.g., fibrosis, atrophy, orretinal epithelial tear in the center of the fovea), study eye.

5. History of (or active) retinal detachment, study eye

6. Uncontrolled glaucoma (defined as IOP > 25 mmHg despite treatment), study eye,or history of steroid-response ocular hypertension/glaucoma in either eye

7. History of intravitreal therapy, (other than anti-VEGF therapy) such asintravitreal steroid injection or investigational product, in the 6 monthsprior to screening, study eye

8. Any prior treatment with photodynamic therapy or laser photocoagulation, studyeye

9. History of glaucoma filtration, vitrectomy, or other procedure that couldaffect drug distribution or clearance, study eye.